India's Safety Alert Against Meftal. Side-effects of Self-medication | Vantage with Palki Sharma скачать в хорошем качестве

India's Safety Alert Against Meftal. Side-effects of Self-medication | Vantage with Palki Sharma

India's Safety Alert Against Meftal. Side-effects of Self-medication | Vantage with Palki Sharma Indian government has issued safety alert against the Meftal-Spas painkiller. Advising against indiscriminate use of Meftal without prescription. This is a prescription drug commonly used without doctor's guidance. Self-medication is prevalent across the world. Overuse of over-the-counter drugs is rampant. And this comes with a long list of problems. In its defence - Blue Cross Laboratories, the makers of Meftal issued the following statement: Blue Cross Laboratories makes Meftal and Meftal-Spas, the brands that are trusted by doctors in India for the treatment of pain, fever, and spasm. They contain mefenamic acid as an active ingredient. We wish to issue a clarification regarding the recent media coverage of the alert issued by the Indian Pharmacopeia Commission (IPC) on mefenamic acid. The alert issued by IPC was to advise Doctors and patients to monitor the possibility of an adverse drug reaction (ADR) of mefenamic acid, which does not in any way impact the safety, efficacy and high quality of the brands that are established and supported by clinical studies and real-world evidence. Mefenamic acid, apart from India (as Meftal and Meftal-Spas) is being prescribed in countries like USA, UK, Japan, etc for more than four decades with billions of doses administered and has benefitted millions of patients. The ADR i.e. DRESS syndrome, mentioned in the IPC alert, is a very rare event that is previously documented in the medical literature, both in India and globally. It is a known ADR of many drugs and published reports are available for paracetamol and ibuprofen. When prescribing any medicine, doctors take patient history and other individual factors into account to reduce the risk of any ADR. The Pharmacovigilance Programme of India (PVPI) operates under the purview of IPC and the Ministry of Health and Family Welfare to collect data on adverse events of all drugs. It works in the interest of patients to ensure the safety and efficacy of all drugs for all disease conditions. Blue Cross Laboratories as a responsible company has a strong pharmacovigilance system internally and supports the efforts of PvPI.” --- Meftal | Self-Medication | India | Safety Alert | Firstpost | World News | Vantage | Palki Sharma #meftal #selfmedication #india #safetyalert #firstpost #vantageonfirstpost #palkisharma #worldnews Vantage is a ground-breaking news, opinions, and current affairs show from Firstpost. Catering to a global audience, Vantage covers the biggest news stories from a 360-degree perspective, giving viewers a chance to assess the impact of world events through a uniquely Indian lens. The show is anchored by Palki Sharma, Managing Editor, Firstpost. By breaking stereotypes, Vantage aims to challenge conventional wisdom and present an alternative view on global affairs, defying the norm and opening the door to new perspectives. The show goes beyond the headlines to uncover the hidden stories – making Vantage a destination for thought-provoking ideas. Vantage airs Monday to Friday at 9 PM IST on Firstpost across all leading platforms. ​ Subscribe to Firstpost channel and press the bell icon to get notified when we go live.    / @firstpost   Follow Firstpost on Instagram:   / firstpost   Follow Firstpost on Facebook:   / firstpostin   Follow Firstpost on Twitter:   / firstpost   Follow Firstpost on WhatsApp: https://www.whatsapp.com/channel/0029...